Novavax (NASDAQ:NVAX) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.24, RTT News reports. The business had revenue of $2.51 million during the quarter, compared to analyst estimates of $4.40 million. During the same period in the prior year, the business earned ($2.40) earnings per share.
NVAX stock traded up $0.09 during midday trading on Friday, hitting $4.59. 858,200 shares of the stock were exchanged, compared to its average volume of 807,410. The stock’s 50-day moving average price is $4.91 and its 200-day moving average price is $4.94. Novavax has a fifty-two week low of $4.01 and a fifty-two week high of $51.60. The stock has a market cap of $106.69 million, a price-to-earnings ratio of -0.46 and a beta of 1.90.
Several analysts have recently commented on NVAX shares. B. Riley set a $35.00 price target on Novavax and gave the company a “buy” rating in a report on Tuesday, September 24th. HC Wainwright lifted their price objective on Novavax from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Oppenheimer reduced their price objective on Novavax from $25.00 to $13.00 and set an “outperform” rating for the company in a report on Tuesday, September 10th. Citigroup reduced their price objective on Novavax from $19.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, September 24th. Finally, Zacks Investment Research cut Novavax from a “hold” rating to a “sell” rating in a report on Friday, October 25th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $31.15.
In other Novavax news, SVP John A. Herrmann III sold 3,643 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $7.07, for a total transaction of $25,756.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John Trizzino sold 5,578 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $5.72, for a total value of $31,906.16. Following the sale, the chief financial officer now directly owns 4,800 shares of the company’s stock, valued at approximately $27,456. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,841 shares of company stock valued at $117,114. 3.30% of the stock is owned by company insiders.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Read More: FAANG Stocks
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.